Abstract:Objectives To detect the early subclinical myocardial injury during and shortly after epirubicin exposure in asymptomatic patients with large B-cell non-Hodgkin lymphoma by two-dimensional speckle tracking imaging and high sensitive cardiac troponin T (hs-cTnT) and to investigate whether alterations of myocardial strains and high sensitive cardiac troponin T could predict future cardiac dysfunction in patients after epirubicin exposure. Methods Seventy-five patients aged 53.9 ± 13.8 years with newly-diagnosed large B-cell non-Hodgkin lymphoma treated with anthracycline were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after chemotherapy completion. After 4–6 months of chemotherapy, echocardiography was followed up. Levels of cTnT were detected with a highly sensitive assay. Longitudinal (LS), circumferential (CS) and radial strain (RS) were calculated using two-dimensional speckle tracking echocardiography. Left ventricular ejection fraction (LVEF) was analysed by real-time 3D echocardiography. Cardiotoxicity was defined according to the guidelines (Cardiac Review and Evaluation Committee of Trastuzumab-associated cardiotoxicity, CREC) as a reduction of the left ventricular ejection fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or an asymptomatic reduction of the LVEF of ≥10% to <55%. Results LVEF remained stable and within normal limits in the whole course of chemotherapy. However it was decreased from 65.0 ± 3.8% at baseline to 60.8 ± 4.9% during follow-up (p = 0.000). Fourteen patients (18.67%) developed cardiotoxicity 4–6 months after treatment. Global LS (-18.5 ± 1.7% vs -16.5 ± 1.9%), CS (-20.9 ± 2.9% vs -19.3 ± 3.5%), RS (39.2 ± 6.4% vs 35.3 ± 5.2%) were markedly reduced and cTnT was elevated from 0.0010 ± 0.0020 ng/ml to 0.0063 ± 0.0089 ng/ml (p all<0.01) at the completion of the third cycle of chemotherapy compared with baseline values. The correlation between the increment of cTnT levels and percentage of global LS deduction was good (rho = 0.60, p < 0.01), and percentage of CS and RS decrease was modest (rho = 0.31, -0.29, respectively, p all <0.01). A >15.9% decrease in longitudinal strain ( sensitivity: 86%, specificity: 75%, AUC = 0.815, P = 0.001) and a >0.004ng/ml elevation in cTnT levels (sensitivity: 79%, specificity: 64%, AUC = 0.757, P = 0.005) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity. The decrease of longitudinal strain between baseline and the third cycle of chemotherapy remained the only independent predictor of cardiotoxicity (p = 0.000). Conclusions Two-dimensional speckle tracking imaging combined with high sensitive cTnT may provide a reliable and accurate non-invasive method to detect subtle myocardial injury and to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy. The decrease of longitudinal strain is the only independent predictor of cardiotoxicity.

BNP As a Marker for Early Prediction of Anthracycline-Induced Cardiotoxicity in Patients with Breast Cancer

Increased epicardial adipose tissue volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

BNP levels and its influencing factors in patients with acute coronary syndrome

Brain Natriuretic Peptide in Early Diagnosis of Chemotherapy-associated Cardiac Toxicity

Assessment of predictors of anthracycline-induced heart failure

Changes in sST2 and NT-proBNP levels predict early cardiac arrhythmia in breast cancer patients treated with anthracycline-containing chemotherapies

Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer

Use of B-type Natriuretic Peptide in Evaluation of Early Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.

P2429Echocardiographic Tei Index Combined with Serum High-Sensitivity Troponin T Assay for Early Diagnosis of Anthracycline-Induced Cardiotoxicity

A-015 Changes of sST2 and NT-proBNP levels predict early cardiovascular toxicity in breast cancer patients treated with anthracycline-containing chemotherapy

[Evaluation of Early Monitoring of Cardiotoxicity Induced by Anthracyclines].

Early Anthracycline-Induced Cardiotoxicity Monitored by Echocardiographic Doppler Parameters Combined with Serum Hs-Ctnt.

GW24-e1764 Speckle Tracking Imaging Combined with High Sensitive Cardiac Troponin T in Early Detection and Prediction of Cardiotoxicity During Anthracycline-based Chemotherapy

Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer

High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury

Ctnt As a Marker for Early Detection for Anthracycline-Induced Cardiotoxicity

Analysis of Cardiovascular Risk Indicators in Older Patients with Cancer

Summed Rest Score in Gated Myocardial Perfusion Imaging is a Good Predicator for Treatment-Related Cardiotoxicity after Anthracycline Chemotherapy in Patients with Diffuse Large B-cell Lymphoma.

Estimation of the value of echocardiographic Tei index combined with serum high-sensitivity cardiac troponin T assay in early diagnosis of anthracycline-induced cardiotoxicity

Current Possibilities of Early Detection of Cardiotoxicity of Cytostatic Treatment